by Biotechnology Focus •
March 3, 2016 •
Business Focus, Deals/M&A/Collaboration, Drug Development, Science Focus •
Comments (0) •
Toronto, ON – The Centre for Addiction and Mental Health (CAMH) and U.S.-based Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression.
Comments are closed.
© 2017 Biotechnology Focus™
Powered by Wordpress. Designed by Themnific™